EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

DHLCA Alleviates Diabetic Kidney Disease via TGR5/FXR Activation and Gut Microbiota Remodeling

Hua Zhou iD, Xiaodie Mu, Huiyue Hu iD, Shuya Zhao, Nan Hu iD, Min Yang, Jingting Jiang

Drug Design, Development and Therapy · 2025-07 · Volume 19 · 6469-6485

DOI: 10.2147/dddt.s530823 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-07. Verfasst von Hua Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Gastrointestinal Microbiome, Diabetic Nephropathies, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledGastrointestinal MicrobiomeDiabetic NephropathiesReceptors, Cytoplasmic and NuclearDiabetes Mellitus, Type 2Lithocholic AcidAnimalsMiceMaleHumansMiddle AgedDiabetes Mellitus, ExperimentalMice, Inbred C57BLFemaleDisease Models, AnimalReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

Takeda G protein-coupled receptor 5bile aciddiabetic kidney diseasefarnesoid X receptorgut microbiota

Substanzen

Receptors, G-Protein-CoupledReceptors, Cytoplasmic and NuclearLithocholic AcidReceptor, Farnesoid X-ActivatedGPBAR1 protein, humanGpbar1 protein, mouse

Autor:innen und Institutionen

  • Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
  • Department of Nephrology, The Second People's Hospital of Hefei, Hefei, 230011, People's Republic of China.
  • Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
  • Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
  • Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
  • Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.

ORCID-Profile: Hua Zhou, Huiyue Hu, Nan Hu

Zitieren

APA

Zhou, H., Mu, X., Hu, H., Zhao, S., Hu, N., Yang, M., & Jiang, J. (2025). DHLCA Alleviates Diabetic Kidney Disease via TGR5/FXR Activation and Gut Microbiota Remodeling. Drug Design, Development and Therapy, Volume 19, 6469-6485. https://doi.org/10.2147/dddt.s530823

Vancouver

Zhou H, Mu X, Hu H, Zhao S, Hu N, Yang M, et al. DHLCA Alleviates Diabetic Kidney Disease via TGR5/FXR Activation and Gut Microbiota Remodeling. Drug Design, Development and Therapy. 2025;Volume 19:6469-6485. doi:10.2147/dddt.s530823

BibTeX
@article{Zhou2025,
  author = {Zhou, Hua and Mu, Xiaodie and Hu, Huiyue and Zhao, Shuya and Hu, Nan and Yang, Min and Jiang, Jingting},
  title = {DHLCA Alleviates Diabetic Kidney Disease via TGR5/FXR Activation and Gut Microbiota Remodeling},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {6469--6485},
  doi = {10.2147/dddt.s530823}
}
Kostenlos starten →